TY  - JOUR
AU  - Prieto-Domínguez, Nestor
AU  - Ordóñez, Raquel
AU  - Fernández, Anna
AU  - García-Palomo, Andres
AU  - Muntané, Jordi
AU  - González-Gallego, Javier
AU  - Mauriz, José L
PY  - 2016
DO  - 10.3389/fphar.2016.00151
SN  - 1663-9812
UR  - https://hdl.handle.net/10668/27600
T2  - Frontiers in pharmacology
AB  - The multikinase inhibitor sorafenib is, at present, the only drug approved for the treatment of hepatocellular carcinoma (HCC), one of the most lethal types of cancer worldwide. However, the increase in the number of sorafenib tumor resistant cells...
LA  - en
KW  - autophagy
KW  - cancer therapeutic
KW  - dug resistance
KW  - hepatocellular carcinoma
KW  - sorafenib
TI  - Modulation of Autophagy by Sorafenib: Effects on Treatment Response.
TY  - research article
VL  - 7
ER  -